perhaps the most fundamental one is that the US Food and Drug Administration (FDA) has a strong preference for data that demonstrate symptom improvement rather than delay in symptom worsening. From a regulatory perspective, there is a good reason for this. Consider a comparison of standard, toxic chemotherapy and a better-tolerated but less efective experimental therapy. Approval based on time to worsening of symptoms might actually make the standard, more efective therapy look worse (in the short run). Tis would clearly be a problem to a regulatory body, allowing inferior therapies to replace more efective therapies merely because they don't make people feel as badly.
However, there is an imperative in oncology drug development that provides us with an incentive to fnd a way to introduce symptom and PRO endpoints more formally into the regulatory scene. First, to maximize the potential beneft observed, virtually all oncology clinical trials restrict eligibility to patients with good performance status. By defnition, these are patients with few or no diseaserelated symptoms. Terefore, there is not much that can be improved upon, so a symptom improvement goal is not realistic. Delay of onset of disease-related symptoms is, however, a meaningful endpoint to patients. Second, and more important, disease symptom beneft and related patient-based outcomes, such as side efect burden and treatment tolerability, are critical to determining whether PFS as an endpoint has any value at all. In the absence of an OS beneft, PFS is a difcult endpoint to place a value upon. On the one hand, delaying cancer progression is likely to confer some beneft to a person's quality of life, not only because of the psychological beneft of knowing one's disease is stable, but also because delaying progression is likely to delay the onset of life-limiting symptoms. On the other hand, treatment itself carries toxicities that can be distressing and life-limiting. In addition, there are costs associated with treatment that are placing an increasing burden on the fnancial wellbeing of patients and their families. To fully appreciate the benefts and risks associated with delaying PFS, these studies require assessment of targeted quality-of-life domains, namely disease symptoms, treatment side efects, acceptability of therapy, and fnancial cost.
With respect to the PRO aspect of oncology clinical trials, the implicit (or perhaps it should be explicit) hypothesis is that the treatment arm associated with a PFS beneft also confers a symptom or other PRO beneft relative to the comparator. Tis is based on the underlying hypothesis that the disease symptom beneft of delaying progression will be greater than any diferences in toxicities that might exist between treatments. To test this hypothesis properly, it is critically important that all living patients be assessed even after progression, for the full follow-up window specifed in the treatment protocol. If, as has been the case in many previous trials, PRO assessment stops at the time of progression, this will introduce a bias in the group com-parison, which typically disadvantages the more efective treatment because it retains more patients, including some who may have progressed on the inferior treatments.
What questions should be asked of patients to evaluate their perspective on treatment beneft? A primary emphasis on symptoms of disease makes sense, with the understanding that some symptoms, such as fatigue and nausea, may be due to both disease and treatment. A secondary emphasis on treatment side efects, and the burden or acceptability of treatment, should ideally also include a measure of patient preferences for continuing active treatment, whether with stable or responding disease parameters. After more than 30 years of studying PROs in oncology clinical trials, we are still working to come up with the best combination of questions to assess this rather complicated set of considerations. Perhaps it is a Holy Grail, but we are moving closer to the goal.
With respect to cost outcomes, although they are not in the mix when it comes to US regulatory review, they are increasingly important to our patients. Often, we fnd that noncytotoxic, targeted therapy provides signifcant clinical beneft above and beyond what is possible with conventional chemotherapy. Tey also tend to carry very high costs, more and more of which must come from the pockets of patients themselves. Tis adds new fnancial burdens to individuals and of course to us collectively, providing ever more incentive to ensure that new therapies that extend PFS are worth their cost. I don't think we can aford to live much longer by PFS alone. It's time we made sure that PFS is worth paying for, and the best source for determining that is our patients. We have all the tools to do this; now we must get better at putting them together.
With this editorial, I invite colleagues around the world to write to the journal with suggestions for how one might go about placing a value on PFS in the absence of a demonstrable OS beneft. For example, what weight should be given to disease symptom relief versus treatment toxicity? How important is it to know whether a symptom like nausea or fatigue is caused by the disease or by the treatment? How does one factor in cost beyond the current unsatisfying methods of cost efectiveness and cost-utility analysis? Please share your thoughts in 1,000 words or fewer and e-mail them to rmatthews@frontlinemedcom.com.
